Emily Becker, MD, discusses the role of AhR agonists, skin barrier function, and steroid-free treatment options for pediatric atopic dermatitis.
|Podcasts|January 8, 2021
Reflecting on 2020, looking toward 2021
Author(s)Miranda Hester
Contemporary Pediatrics sat down with Andrew J. Schuman, MD, FAAP, to discuss his reflections on 2020 and what he thinks may happen in 2021.
Advertisement
2020 will go down as the year when life screeched to a halt for many and health care workers and scientists became the heroes. How will it change medicine and what will 2021 hold?
Contemporary Pediatrics sat down with Andrew J. Schuman, MD, FAAP, to discuss his reflections on 2020 and what he thinks may happen in 2021.
Advertisement
Related to this article
Post hoc data show cariprazine improved both manic and depressive symptoms through 52 weeks in youth aged 10 to 17 years with bipolar I disorder.
CDC data show pediatric CP-CRE incidence rose 92% from 2019 to 2024, driven by NDM-CRE, mostly in children with complex medical needs.
Julie Sweetland, PhD, shares strategies to improve vaccine conversations by explaining the science, acknowledging parental concerns, and building trust.
A meta-analysis of 52 studies links NO2, SO2, and particulate matter to more pediatric atopic dermatitis visits and higher prevalence.
FDA is investigating tumor reports after Zolgensma for SMA, including 2 confirmed cases of vector integration near the GLI1 oncogene.
Jon Matthew Farber, MD, shares his thoughts on the use of noninvasive brain stimulation for ADHD.
Review some of the top stories from the Contemporary Pediatrics website over the last week, and catch up on anything you may have missed.
Advertisement
Advertisement
Trending on Contemporary Pediatrics
1
FDA investigates malignancy risk with SMA gene therapy Zolgensma
2
Cariprazine improves mania and depression in pediatric bipolar I
3
How pediatricians can reframe vaccine conversations
4
Air pollution tied to higher pediatric atopic dermatitis burden
5